Harman, Nicola ORCID: 0000-0001-6958-6466, Wilding, John ORCID: 0000-0003-2839-8404, Curry, Dave, Harris, James, Logue, Jennifer, Pemberton, R John, Perreault, Leigh, Thompson, Gareth, Tunis, Sean, Williamson, Paula R ORCID: 0000-0001-9802-6636 et al (show 1 more authors)
(2019)
Selecting Core Outcomes for Randomised Effectiveness Trials in Type 2 Diabetes (SCORE-IT) - a Patient and Healthcare Professional Consensus on a Core Outcome Set for Type 2 Diabetes.
BMJ Open Diabetes Research and Care, 7 (1).
e000700-.
This is the latest version of this item.
Text
SCORE-IT manuscript V1.0 29-4-19 Revised 2-9-19.pdf - Author Accepted Manuscript Download (356kB) | Preview |
Abstract
Objectives:Heterogeneity in outcomes measured across trials of glucose-lowering interventions for people with type 2 diabetes impacts on the ability to compare findings and may mean that the results have little importance to healthcare professionals and the patients that they care for. The SCORE-IT study (Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes) has addressed this issue by establishing consensus on the most important outcomes for non-surgical interventions for hyperglycemia in type 2 diabetes. Research design and methods:A comprehensive list of outcomes was developed from registered clinical trials, online patient resources, qualitative literature and long-term studies in the field. This list was then scored in a two-round online Delphi survey completed by healthcare professionals, people with type 2 diabetes, researchers in the field and healthcare policymakers. The results of this online Delphi were discussed and ratified at a face-to-face consensus meeting. Results:173 people completed both rounds of the online survey (116 people with type 2 diabetes, 37 healthcare professionals, 14 researchers and 6 policymakers), 20 of these attended the consensus meeting (13 people with type 2 diabetes and 7 healthcare professionals). Consensus was reached on 18 core outcomes across five domains, which include outcomes related to diabetes care, quality of life and long-term diabetes-related complications. Conclusions:Implementation of the core outcome set in future trials will ensure that outcomes of importance to all stakeholders are measured and reported, enhancing the relevance of trial findings and facilitating the comparison of results across trials.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | SCORE-IT Study Team |
Depositing User: | Symplectic Admin |
Date Deposited: | 11 Dec 2019 15:48 |
Last Modified: | 19 Jan 2023 00:13 |
DOI: | 10.1136/bmjdrc-2019-000700 |
Open Access URL: | https://doi.org/10.1136/bmjdrc-2019-000700 |
Related URLs: | |
URI: | https://livrepository.liverpool.ac.uk/id/eprint/3065926 |
Available Versions of this Item
-
Selecting Core Outcomes for Randomised Effectiveness Trials in Type 2 Diabetes (SCORE-IT) - a Patient and Healthcare Professional Consensus on a Core Outcome Set for Type 2 Diabetes. (deposited 21 Oct 2019 09:21)
- Selecting Core Outcomes for Randomised Effectiveness Trials in Type 2 Diabetes (SCORE-IT) - a Patient and Healthcare Professional Consensus on a Core Outcome Set for Type 2 Diabetes. (deposited 11 Dec 2019 15:48) [Currently Displayed]